Literature DB >> 2018120

Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats.

A Flyvbjerg1, K D Jørgensen, S M Marshall, H Orskov.   

Abstract

We investigated the effect of a somatostatin analogue octreotide (SMS) on the stimulatory effect of recombinant human growth hormone (hGH) on insulin-like growth factor I (IGF-I) generation and growth in hypophysectomized rats. Two weeks after hypophysectomy, treatment was given for 11 days with either saline, SMS (100 micrograms/day), hGH (140 micrograms/day), or hGH plus SMS. Compared with saline-injected controls, hGH stimulated body weight gain [1.1 +/- 0.7 vs. 40.9 +/- 0.8 (SE) g, P less than 0.001] and width of epiphysial cartilage (138.0 +/- 4.5 vs. 356 +/- 3.8 microns, P less than 0.001). Combined treatment with hGH and SMS significantly reduced both body weight gain (29.1 +/- 2.5 g, P less than 0.001) and width of epiphysial cartilage (315.3 +/- 5.8 microns, P less than 0.001) compared with the effects of hGH alone. During 11 days of hGH treatment, serum IGF-I increased from 22 +/- 5 to 1,288 +/- 92 micrograms/l (P less than 0.001) but increased only 40% (513 +/- 71 vs. 1,288 +/- 92 micrograms/l, P less than 0.001) when SMS was given in combination with hGH. In gastrocnemius muscle, heart, and lung, but not in liver, kidney, and brain, SMS suppressed organ weight increase when given both with and without hGH substitution. Thymus and gastrointestinal tract weight were significantly reduced in the group receiving SMS alone and tended to be reduced in the hGH-substituted group given SMS as well. Tissue IGF-I was increased in liver, lung, kidney, and heart with hGH treatment (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018120     DOI: 10.1152/ajpendo.1991.260.4.E568

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  5 in total

1.  Sustained-release delivery of octreotide from biodegradable polymeric microspheres.

Authors:  Yun-Seok Rhee; MinJi Sohn; Byung H Woo; B C Thanoo; Patrick P DeLuca; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

Review 2.  Insulin-like growth factor I: an attractive option for chronic heart failure?

Authors:  M Y Donath; J Zapf
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

3.  Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.

Authors:  I Shimon; D Nass; M Hadani
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

4.  Cardiac functions in children with growth hormone deficiency before and during growth hormone-replacement therapy.

Authors:  Osman Ozdemir; Ayhan Abaci; Samil Hizli; Cem Hasan Razi; Ahmet Zulfikar Akelma; Mesut Kocak; Fatih Mehmet Kislal
Journal:  Pediatr Cardiol       Date:  2011-04-07       Impact factor: 1.655

5.  Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

Authors:  Robert D Murray; Kiwon Kim; Song-Guang Ren; Marjorie Chelly; Yutaka Umehara; Shlomo Melmed
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.